desipramine has been researched along with Atherogenesis in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, M | 1 |
| You, B | 1 |
| Wang, X | 1 |
| Huang, J | 1 |
| Zhou, M | 1 |
| Shi, R | 1 |
| Zhang, G | 1 |
1 other study available for desipramine and Atherogenesis
| Article | Year |
|---|---|
Desipramine enhances the stability of atherosclerotic plaque in rabbits monitored with molecular imaging.
Topics: Animals; Atherosclerosis; Atorvastatin; Desipramine; Molecular Imaging; Plaque, Atherosclerotic; Rab | 2023 |